Regen Biologics' collagen meniscus implant shows promise in early studies, CEO says.
This article was originally published in The Gray Sheet
Executive Summary
ReGEN BIOLOGICS' COLLAGEN MENISCUS IMPLANT FEASIBILITY STUDY resulted in seven of nine patients describing their knees as "nearly normal" after treatment with the implant, ReGen Chief Executive Officer Michael Egan reported at the Hambrecht & Quist life sciences conference in San Francisco. In addition, seven of nine patients showed "marked improvement from their pre-op status," and all patients returned to activities of daily living with minimal or no pain.